AMB-05X (AmMax Bio, Inc.) is recruiting for a Phase 1/2 clinical trial on a monoclonal antibody local injection for the treatment of TGCT of the knee. This means a man-made protein is locally injected into the joint to block the growth and recruitment of other cells, leading to tumor shrinkage. The injection is ultrasound guided, like shown.
In the Phase II expansion trial, other disease locations such as the ankle and hip will be included. This trial intends to evaluate the effectiveness safety, toxicity, and tolerability of AMB-05X as a 24 week treatment.
AMB-05X is administered as a joint injection to the knee for 24 weeks (1 injection every 4 weeks, 6 injections total). AMB-05X uses a monoclonal antibody that is designed to target CSF1 and block it from signaling to TGCT and surrounding cells.
A MRI is taken before treatment and after to measure tumors and determine effectiveness.